HLA Class I Tissue Typing for Patient at Chughtai Lab

HLA Class I Tissue Typing for Patient at Chughtai Lab

Human Leukocyte Antigen (HLA) Class I Tissue Typing is a highly specialized molecular diagnostic procedure that identifies the specific genetic markers present on the surface of almost all nucleated cells in the human body. These markers, classified under the Major Histocompatibility Complex (MHC) on chromosome 6, include the HLA-A, HLA-B, and HLA-C loci. The primary function of HLA Class I molecules is to present intracellular peptides to CD8+ cytotoxic T cells, playing a pivotal role in the immune system’s ability to distinguish self from non-self. At Chughtai Lab, this test is performed using advanced molecular biology techniques to ensure the highest level of resolution and clinical accuracy, which is vital for patients undergoing organ transplantation, bone marrow transplantation, or requiring specialized disease diagnosis.

The clinical importance of HLA Class I Tissue Typing cannot be overstated. It serves as the biological foundation for histocompatibility matching. In the context of allogeneic transplantation, a close match between the HLA markers of the donor and the recipient is critical to minimize the risk of graft rejection and Graft-Versus-Host Disease (GVHD). Beyond transplantation, specific HLA Class I alleles are strongly associated with various autoimmune diseases, inflammatory conditions, and severe drug hypersensitivity reactions. By utilizing state-of-the-art technology, Chughtai Lab provides precise allelic identification that guides clinicians in making life-saving therapeutic decisions, optimizing immunosuppressive regimens, and ensuring patient safety.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is essential to ensure sample integrity and accurate molecular analysis. Patients undergoing HLA Class I Tissue Typing at Chughtai Lab should observe the following guidelines:

• No Fasting Required: There is no need to fast before this test. Patients may eat and drink normally prior to sample collection.
• Disclose Medical History: It is critical to inform the laboratory staff and your physician if you have had a recent blood transfusion (within the last 3 months) or a history of bone marrow transplantation, as donor DNA can temporarily or permanently interfere with molecular typing results.
• Medication Reporting: Continue taking all prescribed medications as directed by your physician, but ensure that a complete list of these medications is provided to the laboratory staff.
• Hydration: Staying well-hydrated is recommended, as it makes the venipuncture process smoother and more comfortable.

During the Procedure

The sample collection process for HLA Class I Tissue Typing is straightforward and adheres to strict clinical protocols to prevent contamination and maintain sample traceability:

• Patient Identification: The phlebotomist will verify your identity using at least two unique identifiers (such as your name and lab registration number) to ensure absolute accuracy in labeling.
• Aseptic Technique: The phlebotomist will locate a suitable vein, typically in the inner elbow (antecubital fossa), and cleanse the skin thoroughly with an antiseptic solution to prevent contamination.
• Venipuncture: A sterile, single-use needle will be inserted into the vein to collect a whole blood sample. The blood is drawn directly into an EDTA (purple-top) tube, which contains an anticoagulant that preserves cell integrity and prevents DNA degradation.
• Duration: The actual blood draw takes less than two minutes. The entire visit, including registration and post-draw care, is completed quickly.
• Post-Collection Care: After removing the needle, gentle pressure is applied to the puncture site with a sterile cotton ball, followed by the application of a small bandage. Patients are advised to keep the bandage on for at least an hour and avoid heavy lifting with that arm for the rest of the day.
• Safety and Comfort: The procedure is minimally invasive and carries minimal risk, similar to a routine blood test. Some patients may experience mild, temporary bruising or soreness at the injection site.

When is a HLA Class I Tissue Typing for Patient Performed?

Solid Organ Transplantation Matching

HLA Class I Tissue Typing is routinely performed prior to solid organ transplants, such as kidney, heart, lung, or liver transplantations. Matching the HLA-A, HLA-B, and HLA-C antigens between the donor and the recipient is critical to reduce the likelihood of hyperacute, acute, or chronic graft rejection. A closer HLA match correlates with improved long-term graft survival and reduces the necessity for high-dose, potentially toxic immunosuppressive therapies post-transplant.

Hematopoietic Stem Cell and Bone Marrow Transplantation

For patients diagnosed with hematologic malignancies like leukemia, lymphoma, or severe aplastic anemia, hematopoietic stem cell transplantation (HSCT) is often the primary curative option. HLA Class I typing is performed at a high-resolution level for both the patient and potential family or registry donors. A precise match is mandatory to prevent Graft-Versus-Host Disease (GVHD), a life-threatening complication where the donor’s immune cells recognize the recipient’s tissues as foreign and mount an immune attack against them.

Diagnosis of Spondyloarthropathies and Autoimmune Diseases

Physicians frequently request HLA Class I typing, specifically for the HLA-B27 allele, when evaluating patients presenting with symptoms of chronic inflammatory back pain, joint stiffness, or recurrent eye inflammation. The presence of the HLA-B27 antigen is strongly associated with a group of inflammatory joint diseases known as spondyloarthropathies, most notably Ankylosing Spondylitis, Reactive Arthritis, and Acute Anterior Uveitis. Identifying this genetic marker helps confirm the diagnosis in the early stages of these diseases.

Pharmacogenomic Screening for Drug Hypersensitivity

HLA Class I typing is utilized as a preventive screening tool before initiating certain high-risk medications. For example, screening for the HLA-B*57:01 allele is mandatory before prescribing the antiretroviral drug Abacavir to HIV patients, as individuals carrying this allele are at an extremely high risk of developing a severe, potentially fatal hypersensitivity reaction. Similarly, screening for the HLA-B*15:02 allele is recommended in specific populations before starting Carbamazepine therapy to prevent life-threatening skin reactions like Stevens-Johnson Syndrome (SJS).

Investigation of Platelet Transfusion Refractoriness

Patients who receive frequent platelet transfusions, such as those undergoing intensive chemotherapy, may develop antibodies against foreign HLA Class I antigens present on the transfused platelets. This immune response leads to the rapid destruction of transfused platelets, a condition known as platelet refractoriness. HLA Class I typing of the patient allows hematologists to identify compatible, HLA-matched platelet donors, ensuring that subsequent transfusions are therapeutically effective.

What Does a HLA Class I Tissue Typing for Patient Detect?

HLA Class I Tissue Typing is designed to detect specific alleles across the three major Class I loci. The test identifies the unique genetic sequence inherited from each parent, providing a detailed profile of the patient’s histocompatibility antigens. Specifically, the test detects:

• HLA-A Alleles: Identification of specific variants at the HLA-A locus (e.g., HLA-A*01, HLA-A*02, HLA-A*03, HLA-A*11, HLA-A*24), which are critical for general tissue matching and identifying specific disease associations.
• HLA-B Alleles: Identification of highly polymorphic variants at the HLA-B locus, which is the most diverse locus in the HLA system. This includes detecting clinically significant alleles such as HLA-B*27, HLA-B*57:01, HLA-B*15:02, and HLA-B*58:01.
• HLA-C Alleles: Identification of alleles at the HLA-C locus (e.g., HLA-C*06, HLA-C*07), which play an important role in natural killer (NK) cell regulation and are associated with conditions like psoriasis vulgaris.
• Allelic Polymorphisms: Detection of precise nucleotide sequence variations that define individual alleles, allowing for low, medium, or high-resolution typing depending on the clinical requirement.
• Mismatched Alleles: In donor-recipient pairing, the test detects the presence and number of mismatched HLA antigens, which directly correlates with the immunological risk of transplant rejection.
• HLA-B*27 Positivity: Specifically detects the presence of the HLA-B27 antigen, confirming a genetic predisposition to Ankylosing Spondylitis and related spondyloarthropathies.
• HLA-B*57:01 Positivity: Detects the specific allele associated with severe hypersensitivity reactions to the drug Abacavir.
• HLA-B*15:02 Positivity: Detects the genetic marker that predisposes patients of certain ancestries to Carbamazepine-induced Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).
• HLA-B*58:01 Positivity: Detects the allele associated with a high risk of severe cutaneous adverse reactions (SCAR) to Allopurinol, a common medication used to treat gout.
• HLA-B*51 Positivity: Identifies the allele strongly associated with Behçet’s disease, a rare multisystem inflammatory disorder.
• HLA-B*35 Positivity: Detects the allele linked to subacute thyroiditis and rapid progression of HIV infection.
• Homozygosity vs. Heterozygosity: Determines whether a patient has inherited identical alleles (homozygous) or different alleles (heterozygous) at each HLA Class I locus, which affects the complexity of finding a matching transplant donor.

Turnaround Time and Report Access at Chughtai Lab

Chughtai Lab is committed to delivering highly accurate diagnostic results within an optimal timeframe. Because HLA Class I Tissue Typing involves complex molecular techniques, including Polymerase Chain Reaction (PCR) and Next-Generation Sequencing (NGS), the processing time is longer than routine blood tests. Typically, the turnaround time for HLA Class I Tissue Typing is between 5 to 7 working days. This allows our specialized molecular pathologists to perform rigorous quality control checks and ensure the absolute accuracy of the genetic profile.

Once the analysis is complete, Chughtai Lab offers multiple convenient ways for patients and clinicians to access the diagnostic report. Reports can be downloaded directly from the official Chughtai Lab website using the patient’s case number and password. Additionally, patients can access their results via the user-friendly Chughtai Lab mobile application, receive them directly on WhatsApp, or opt for home delivery of printed reports. This seamless digital integration ensures that critical transplant and diagnostic data are available to healthcare providers without delay.

HLA Class I Tissue Typing for Patient Findings Overview

The following table outlines the parameters evaluated during HLA Class I Tissue Typing, along with normal and potential abnormal findings and their clinical implications:

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
HLA-A Locus Typing	Normal distribution of inherited maternal and paternal HLA-A alleles.	Presence of specific alleles linked to disease susceptibility or mismatch with a prospective transplant donor.
HLA-B Locus Typing	Normal distribution of inherited maternal and paternal HLA-B alleles.	Presence of high-risk alleles (e.g., HLA-B*27, HLA-B*57:01) or mismatch with a prospective transplant donor.
HLA-C Locus Typing	Normal distribution of inherited maternal and paternal HLA-C alleles.	Presence of alleles associated with autoimmune conditions (e.g., HLA-C*06) or mismatch in donor-recipient pairs.
HLA-B*27 Status	Negative (No HLA-B*27 allele detected).	Positive (Strongly associated with Ankylosing Spondylitis, Reactive Arthritis, and Anterior Uveitis).
HLA-B*57:01 Status	Negative (Low risk of Abacavir hypersensitivity).	Positive (High risk of severe, life-threatening hypersensitivity reaction to Abacavir; drug is contraindicated).
HLA-B*15:02 Status	Negative (Standard risk of Carbamazepine-induced skin reactions).	Positive (High risk of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis; Carbamazepine is contraindicated).
HLA-B*58:01 Status	Negative (Standard risk of Allopurinol hypersensitivity).	Positive (High risk of severe cutaneous adverse reactions to Allopurinol; alternative therapy recommended).
Donor-Recipient Compatibility	High-grade match (e.g., 6/6 or 8/8 allele match across Class I and Class II loci).	Low-grade match or complete mismatch, indicating a high risk of graft rejection or Graft-Versus-Host Disease.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for HLA Class I Tissue Typing for Patient?

• Experienced Healthcare Professionals: Our molecular diagnostics division is led by highly qualified consultant pathologists and molecular geneticists with extensive experience in histocompatibility and immunogenetics.
• Patient-Focused Care: We prioritize patient comfort and convenience, offering a compassionate environment at all our collection centers.
• Quality Diagnostic Services: Chughtai Lab adheres to strict international quality control standards, ensuring that every molecular test is performed with maximum precision.
• Professional Reporting: Our reports provide detailed, clear, and clinically actionable genetic data to assist transplant teams and physicians in making critical decisions.
• Modern Diagnostic Approach: We utilize advanced molecular technologies, including PCR-SSP and high-resolution sequencing, to deliver state-of-the-art tissue typing services.
• Comfortable Environment: Our state-of-the-art laboratory facilities and collection centers are designed to provide a clean, safe, and welcoming experience for patients.
• Convenient Location: With an extensive network of diagnostic centers and collection points across Pakistan, finding a Chughtai Lab near you is easy and convenient.
• Commitment to Accurate Diagnosis: We are dedicated to providing timely, reliable, and evidence-based diagnostic results that form the cornerstone of successful patient care and transplant outcomes.